Trump’s 50% Tariffs Reach Canadian Medical-Test Supplies as Ontario Exporter Warns of Higher U.S. Costs

35,000+ smart investors are already getting financial news, market signals, and macro shifts in the economy that could impact their money next with our FREE weekly newsletter. Get ahead of what the crowd finds out too late. Click Here to Subscribe for FREE.

A trade dispute that has already reached Canadian factories, farms and resource companies is now touching a less obvious corner of cross-border commerce: products used to help ensure medical tests work properly. Beginning October 30, selected Canadian diagnostic and laboratory reagents will face an additional 50% U.S. tariff under President Donald Trump’s latest modification of Section 338 duties.

Mississauga-based Microbix Biosystems says some of its laboratory quality-assessment products appear to fall within the newly targeted tariff classifications. The company’s warning is notable because these products are sold to diagnostic companies and laboratories that use them to validate tests and monitor testing performance. Microbix says U.S. importers will bear the tariff at the border, potentially making the controls more expensive for American customers and raising a difficult question for specialized suppliers: who ultimately absorbs a 50% trade penalty when switching products is neither quick nor simple?

Diagnostic Reagents Are Now Inside the 50% Tariff Net

The latest change stems from an October 23 presidential proclamation modifying the products covered by the United States’ Section 338 tariffs on Canada. The revised list takes effect at 12:01 a.m. Eastern time on October 30. Among the newly included classifications are HTS 3822.19.00, covering certain diagnostic or laboratory reagents, and HTS 3822.90.00, covering certified reference materials associated with laboratory and diagnostic work. The measure does not amount to a blanket 50% tariff on every Canadian medical product, but it brings specific testing-related supplies directly into the trade fight.

That distinction matters. The regular U.S. tariff schedule lists the general duty rate for these categories as free, while the new Section 338 action adds a 50% duty specifically to covered Canadian goods. The White House also says the Section 338 duties apply even when products otherwise qualify under the United States-Mexico-Canada Agreement. For companies whose products fall within those classifications, longstanding preferential access to the American market therefore does not shield them from this particular tariff measure.

Microbix Says Its Quality-Control Products May Be Affected

Microbix Biosystems disclosed the potential impact on October 28, two days before the revised tariffs are scheduled to take effect. The Mississauga life-sciences manufacturer said some of its Quality Assessment Products, known as QAPs, appear to be included in the classifications for diagnostic and laboratory reagents. Microbix employs roughly 120 people and reported C$18.6 million in revenue in fiscal 2025, making it a relatively small company compared with multinational diagnostic giants but an established supplier within the global testing industry.

Its business reaches well beyond Ontario. Microbix says its products are available in more than 30 countries, while its antigens are used by approximately 100 diagnostic manufacturers. QAPs and related reference materials are sold to diagnostics companies, clinical laboratories and organizations involved in proficiency testing. That international footprint makes the tariff issue more than a theoretical customs problem. For shipments entering the United States under affected classifications, the additional duty can alter the economics of an established supplier relationship almost overnight, even when the underlying product has not changed.

These Products Help Laboratories Check Whether Tests Are Working

Quality-control materials rarely receive the public attention given to test machines, medicines or hospital equipment, but they serve an important function behind the scenes. Microbix describes its QAPs as external controls designed to resemble patient specimens. Depending on the product, they can contain inactivated pathogens or synthetic genomic material and are used to monitor multiple parts of a diagnostic workflow, including sample processing, extraction, target detection and analysis.

The broader laboratory system places considerable importance on these controls. U.S. public-health guidance describes quality assessment as a process for monitoring testing and correcting problems, while Clinical and Laboratory Standards Institute guidance emphasizes proficiency testing and external quality assessment for molecular diagnostics. Microbix sells controls for areas including respiratory infections, sexually transmitted infections, HPV and gastrointestinal testing. Some products can also be used for operator training and the verification of new testing systems. They do not diagnose a patient by themselves, but they help laboratories and manufacturers establish confidence that systems intended to produce patient results are performing as expected.

U.S. Importers Face the Immediate Tariff Bill

Tariffs on imports are collected in the United States from the importer of record, rather than being a bill sent by Washington to the Canadian manufacturer. U.S. Customs and Border Protection requires importers to deposit estimated duties during the entry process. Microbix therefore warned that the new duty will increase costs for U.S. buyers or importers bringing affected Canadian products into the country. A shipment with a customs value of US$10,000, for example, would face US$5,000 in additional Section 338 duty if fully subject to the 50% rate, before considering any other applicable charges.

What happens after that payment depends on commercial negotiations. An importer can absorb some of the cost, increase prices, ask the Canadian supplier for concessions or seek another source. Research on recent U.S. tariff episodes shows why the cost issue cannot simply be dismissed as a foreign-exporter problem. Studies covering tariffs imposed in 2018 through 2026 have generally found substantial pass-through into prices paid by American importers, with some of the burden subsequently reaching consumers or other downstream buyers.

Switching Suppliers May Require More Than Finding a Cheaper Product

Microbix argues that its QAPs are difficult to replace quickly because customers have incorporated them into diagnostic-testing workflows that require validation. The company has cautioned that persistent tariffs could eventually lead U.S. customers either to ask Microbix to share the tariff burden or to investigate American alternatives. But the decision to substitute a control material is more complicated in a regulated laboratory environment than replacing a routine office or industrial supply.

U.S. laboratory requirements help explain that friction. Clinical laboratories introducing certain new test systems must verify performance characteristics before reporting patient results, while laboratory quality-control procedures are expected to monitor the accuracy and precision of testing processes. Microbix itself has also described lengthy supplier-qualification work with major diagnostic manufacturers, including reviews of manufacturing, quality assurance and regulatory systems. That does not mean a customer can never change suppliers. It does mean that qualification, documentation and workflow considerations may matter alongside price, giving established products a degree of practical stickiness even when tariffs dramatically alter their landed cost.

Microbix Has Significant Revenue Tied to U.S. Customers

The potential exposure is substantial relative to Microbix’s size. For the nine months ended June 30, 2026, the company reported approximately C$4.2 million in QAP sales. Microbix estimates that roughly C$3.4 million of that amount came from U.S.-based clients, meaning about four-fifths of its QAP revenue during the period was connected to American customers. Total company revenue from U.S.-based clients reached approximately C$5.5 million over the same nine months.

Those numbers do not mean Microbix will suddenly lose that revenue once the tariffs begin. The company has not yet quantified either the short-term or long-term financial effect and says it will update its outlook as the consequences become clearer. Still, the numbers show why management is watching the situation closely. Microbix reported total revenue of C$11.7 million during those nine months, while QAP sales were one of the areas showing growth. A sudden cost increase in a market responsible for millions of dollars in sales creates pressure even if customers continue ordering at existing volumes.

Washington Is Reshuffling the Tariff List, Not Simply Expanding It

The October change illustrates how fluid the Canada-U.S. tariff system has become. Washington is removing 22 tariff classifications from the Section 338 list while adding roughly 100 others. Products receiving relief include certain plywood, packaging materials, refrigeration equipment and machinery. Newly targeted categories range from shampoos and flooring to valves, carpets, electrosurgical instruments, diagnostic reagents and certified reference materials.

The White House says the changes are intended to better serve the U.S. public interest while maintaining pressure on Canada over what the administration characterizes as discriminatory treatment of American commerce. The original Section 338 actions were tied to disputes involving Canadian treatment of U.S. autos, alcohol and dairy. Canada disputes Washington’s characterization and has imposed retaliatory measures of its own. The resulting system can create unusual outcomes: one American industry can receive tariff relief on Canadian inputs while another suddenly faces higher costs. For businesses, that makes tariff classification and the exact date goods enter U.S. commerce increasingly important operational details.

Ontario Businesses Are Already Being Pushed to Adapt

Microbix’s situation is part of a broader challenge facing Ontario exporters that built their businesses around comparatively open access to the American market. The Ontario Chamber of Commerce surveyed 851 organizations between late July and mid-August and found that almost 40% were already taking measures such as diversifying suppliers, pursuing new markets or strengthening operations in response to trade disruption. The chamber has described market diversification as one of the few responses businesses can control directly when U.S. access becomes more expensive or unpredictable.

Ontario has also expanded programs aimed at companies affected by Section 338 and other American tariffs. The province’s Protect Ontario Financing Program offers up to C$1 billion in liquidity support for qualifying businesses facing tariff-related working-capital pressure. That does not eliminate the duties paid by American importers, nor does it guarantee that an individual company will qualify. Instead, it reflects the wider economic concern: repeated tariff changes can squeeze margins, complicate contracts and force businesses to reconsider hiring, investment and export strategies even before customers actually disappear.

A Canada-U.S. Deal Remains the Biggest Near-Term Wildcard

The timing is particularly awkward because Canada and the United States are again talking about a possible trade settlement. Trump said at an October 25 rally in Port Huron, Michigan, that he expected the dispute to be settled “pretty soon,” although he offered few specifics. Prime Minister Mark Carney said the next day that discussions had intensified slightly and argued that any recent progress resulted from Washington moving closer to Canada’s position.

Expectations nevertheless remain uncertain. A Canadian government official told The Canadian Press on October 27 that talks had produced only “limited progress,” despite public suggestions from both governments that a deal could be possible. For Microbix and its American customers, that leaves two competing scenarios. The new 50% duty is scheduled to take effect October 30 and businesses have to plan around it as written. At the same time, an agreement could reduce or remove some tariffs later. Until something is signed and implemented, specialized medical-testing supplies have become another example of how the Canada-U.S. trade conflict can reach far beyond headline industries such as cars, steel and aluminum.

This Options Discord Chat is The Real Deal

While the internet is scoured with trading chat rooms, many of which even charge upwards of thousands of dollars to join, this smaller options trading discord chatroom is the real deal and actually providing valuable trade setups, education, and community without the noise and spam of the larger more expensive rooms. With a incredibly low-cost monthly fee, Options Trading Club (click here to see their reviews) requires an application to join ensuring that every member is dedicated and serious about taking their trading to the next level. If you are looking for a change in your trading strategies, then click here to apply for a membership.